March Biosciences MB-105 Dosed in First T-Cell Lymphoma Patient
March Biosciences has dosed the first patient in a Phase 2 clinical trial for MB-105, a CD5-targeted CAR-T cell...
Kymera Doses First Patient in KT-621 Atopic Dermatitis Trial
Kymera Therapeutics has initiated its BroADen Phase 1b clinical trial for KT-621, an oral STAT6 degrader, in patients with...
Savolitinib Shows Promise in Gastric Cancer: Phase II Trial Completed
HUTCHMED has completed enrollment for the registration phase of its Phase II savolitinib trial in gastric cancer patients with...
GeneSight Test Reduces Psychiatric Hospitalizations in Depression Patients
A study published in the Journal of Clinical Psychopharmacology revealed that patients with major depressive disorder experienced fewer psychiatric...
Achieve Life Sciences Publishes Smoking Cessation Trial Results in JAMA
Achieve Life Sciences announced complete results from its ORCA-3 trial, published in JAMA Internal Medicine, demonstrating cytisinicline’s efficacy in...
FDA Grants Orphan Drug Designation to TPST-1495 for FAP Treatment
Tempest Therapeutics announced that the FDA granted Orphan Drug Designation to TPST-1495 for treating Familial Adenomatous Polyposis (FAP). TPST-1495...
Tovecimig Dosed in First-Line Biliary Tract Cancer Trial
Compass Therapeutics has initiated the first patient dosing in an Investigator Sponsored Trial (IST) at MD Anderson Cancer Center....
Elutia Launches Elupro™ Registry Study
Elutia Inc. launched a clinical study to gather real-world data on patient outcomes using EluPro, its FDA-cleared antibiotic-eluting bioenvelope...
Regeneron Eylea HD 8 mg Update: Biologics License Application
Regeneron Pharmaceuticals received a Complete Response Letter (CRL) from the FDA regarding its application to extend EYLEA HD’s dosing...
Sernova Secures $4M Loan for Clinical Development
Sernova Biotherapeutics secured a CAD$4 million term loan from Navigate Private Yield Fund LP III. The loan, which matures...